For example, in the case of HER2-positive breast cancer, resistance to HER2-targeted therapies, such as trastuzumab, can occur through mutations in the HER2 receptor or the activation of alternative pathways like the PI3K/Akt/mTOR signaling cascade [81]. Here, MTOR is linked to breast carcinoma.